SpringWorks begins Phase 3 trial of desmoid tumor treatment in adults
Category: #health  By Mateen Dalal  Date: 2019-05-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

SpringWorks begins Phase 3 trial of desmoid tumor treatment in adults

The company is looking forward to enrolling patients with desmoid tumors to confirm the clinical benefits of nirogacestat

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, has reportedly announced the beginning of Phase 3 “DeFi” (Desmoid/Fibromatosis) study for evaluating nirogacestat, a selective, oral and small molecule gamma-secretase inhibitor, to treat adult patients having progressing desmoid tumors.

Seemingly, desmoid tumors are sporadic and are often disfiguring and debilitating soft-tissue tumors which can aggressively attack surrounding healthy tissues, including blood vessels joints, nerves, internal organs, and muscles. Based on their location and size, desmoid tumors can cause substantial morbidities, including internal bleeding, severe pain, debilitating loss of range of motion, disfigurement, and in rare cases desmoid tumor scan be lethal.

Sources familiar with the matter mentioned that an estimated 1,000 to 1,500 novel cases of desmoid tumors are diagnosed every year in the United States. For the treatment of desmoid tumors, there are presently no therapies approved by the U.S. FDA.

Chief Executive Officer of SpringWorks Therapeutics, Saqib Islam stated that those patients who are living with these debilitating tumors, the DeFi trial represents a significant step forward and could result in the first approved treatment for this underserved patient community.

Apparently, the company is looking forward to enrolling patients with desmoid tumors to confirm the clinical benefits of nirogacestat.

In June 2018, the FDA approved Orphan Drug designation for nirogacestat for the treatment of patients who were suffering from desmoid tumors, and in November 2018, the FDA granted Fast Track designation for nirogacestat in the treatment of adult patients with, unresectable, progressive, refractory or recurrent desmoid tumors or deep fibromatosis.

For the uninitiated, the DeFi trial is a double-blind, randomized, placebo-controlled, global Phase 3 trial for evaluating the efficacy, tolerability, and safety of nirogacestat in adult patients with progressing desmoid tumors. The study will enrol around 100 adult patients, who will receive placebo or 150 mg of nirogacestat twice daily.

Source Credit: https://www.springworkstx.com/wp-content/uploads/2019/05/DeFi-Study-Initiation-Press-Release.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Peraton to acquire innovative IT solutions provider Solers Inc.
Peraton to acquire innovative IT solutions provider Solers Inc.
By Mateen Dalal

Virginia-based Peraton, a defense and intelligence contractor owned by private equity firm Veritas Capital, reportedly announced that it has signed a definitive agreement to acquire Solers Inc., a leading provider of software development and cybersec...

Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
By Mateen Dalal

A clinical-stage immune-oncology company, Forty Seven, Inc., that works to develop therapies targeting cancer immune evasion pathways, has revealed clinical data from Phase 1b/2. The company is evaluating a new drug combination of Recombinant Human A...

FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
By Mateen Dalal

NuCana is on its way to open a Global Phase III study of Acelarin in combination with cisplatin for patients who are suffering from the disease in 2019 NuCana plc recently announced that it has received Orphan Drug Designation for Acelarin, an inves...